Drugs / OPB-31121
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT00955812 | Jun 2009 → Nov 2012 | neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01029509 | Jul 2008 → Aug 2011 | leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT00657176 | Mar 2008 → Mar 2009 | cancer | Korea Otsuka Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT00511082 | Dec 2007 → Dec 2009 | non-Hodgkin lymphoma, plasma cell myeloma | Otsuka Beijing Research Institute | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01406574 | Jul 2011 → Mar 2014 | hepatocellular carcinoma | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OPB-31121 | “This is an investigational study. OPB-31121 is not FDA approved or commercially available.” NCT01029509 ↗ |
| Action | Inhibit | “an oral inhibitor of STAT3” PMID 24819685 ↗ May 2014 |
| Route | Oral | “Mode of Administration: oral administration of OPB-31121 once daily” NCT00511082 ↗ |
| Target | STAT3 | “an oral inhibitor of STAT3” PMID 24819685 ↗ May 2014 |